Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE), a clinical-stage drug developer targeting degenerative retinal diseases with significant unmet medical needs, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 4:00 pm ET.
The presentation webcast and 90-day replay will be available in the Events section of Belite Bio’s investor relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BLTE
On Jun 2, the day this news came out, BLTE closed 8.21% below the previous close.
Data tracked by StockTitan Argus for the Jun 2 session.
Key Figures
- Conference date/time
- June 8, 2026, 4:00 pm ET
- Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
- Webcast archive period
- 90 days
- Replay availability after the conference presentation
- Cash balance
- $276.4M
- Cash and cash equivalents as of March 31, 2026 (6-K)
- U.S. treasuries
- $522.2M
- U.S. treasury bills and notes as of March 31, 2026 (6-K)
- GAAP net loss
- $26.9M
- Q1 2026 GAAP net loss, wider year over year (6-K)
- Beneficial ownership
- 1,253,935 shares (3.1%)
- Ordinary shares beneficially owned by Yu-Hsin Lin (Schedule 13G/A)
- Shares outstanding
- 40,085,091 shares
- Ordinary shares outstanding as of March 31, 2026 (Schedule 13G/A)
- Short interest
- 5.59%
- Short interest as a percent of float from risk context
Historical Context
-
Q1 2026 results plus NDA progress and commercialization hiring details.
-
Swiss orphan status and Phase 3 success metrics for tinlarebant.
-
Retina China 2026 oral presentation of DRAGON topline data.
-
Scheduling Q1 2026 results webcast and business update call.
-
Retinal summit talk on DRAGON topline efficacy and safety results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 pm ET.
Webcast Link Instructions
Webcasts of the presentations can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.
Media and Investor Relations Contacts:
Jennifer Wu / ir@belitebio.com
Argot Partners / belite@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.